There is much talk here and promotion by SPL of their DEP...

There is much talk here and promotion by SPL of their DEP Clinical Trials. There seems expectation that successful trial will lead income and thus to a big rise in SPL's share price? What is not clear to me, as med/pharma is not my field, is exactly how a successful DEP trial will lead to INCOME for SPL and so an uptick in share price?

Copied below is from SPL Clinical Trials publication. In response can any HC poster (there are several skilled in this area) tell us all the path from a successful DEP docetaxel Phase 2 trial to money? And maybe comment on the time lines?

I realise such commentary is speculative and carries the usual caveats but will be useful. Perhaps all this has been posted on HC already and I've just missed it.

Current Clinical Trials

• DEP^® docetaxel – Phase 2
• DEP^® cabazitaxel – Phase 1 / 2
• DEP^® irinotecan – Phase 1 / 2

DEP^® docetaxel – Phase 2

Status: Recruiting patients

• Open-label, two-stage design
• Objectives are to establish anti-tumour activity (efficacy) and safety of DEP^® docetaxel (at the Recommended phase 2 Dose (RP2D) of 60mg/m2)
• First stage to enrol ~20 patients with either lung or prostate cancer (the key approved indications for standard docetaxel (e.g. Taxotere^®))
• Second stage to enrol a further 20 patients (tumour types based on results from the first stage)
• Also investigating the potential benefits of combining DEP^® docetaxel with another anti-cancer agent, nintedanib (Vargatef^®)